NCT03035422 (SET-HAPLO) is a NA clinical trial of Sequential Packaging (SET) in Refractory Acute Myeloid Leukemia, sponsored by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation.

What drugs are being tested in NCT03035422?

Interventions in NCT03035422: Sequential Packaging (SET), Transfusion graft, Prevention of GVHD, Care supports, Lymphocyte injection of prophylactic donor (PDLI).

What condition does NCT03035422 study?

NCT03035422 studies Refractory Acute Myeloid Leukemia.

Is NCT03035422 still recruiting?

NCT03035422 is currently completed. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT03035422: SET-HAPLO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia

Completed NA Last updated 25 July 2022

What this trial tests

NA trial testing Sequential Packaging (SET) in Refractory Acute Myeloid Leukemia in 24 participants. Completed in 18 December 2021.

Timeline

15 January 2018

Primary endpoint
18 December 2021

18 December 2021

Quick facts

Lead sponsor	Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	24
Start date	15 January 2018
Primary completion	18 December 2021
Estimated completion	18 December 2021
Sites	1 location across France

Drugs / interventions tested

Sequential Packaging (SET) — full drug profile →
Transfusion graft — full drug profile →
Prevention of GVHD — full drug profile →
Care supports — full drug profile →
Lymphocyte injection of prophylactic donor (PDLI) — full drug profile →

Conditions studied

Refractory Acute Myeloid Leukemia — all drugs for Refractory Acute Myeloid Leukemia →

Sponsor

Association for Training, Education, and Research in Hematology, Immunology, and Transplantation

Who can join

Adults 18 to 60, any sex, with Refractory Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, et al · · 2020 · cited 179× · PMID 32002302 · DOI 10.1080/2162402x.2019.1703449

Verify or expand the search:

Other trials of Sequential Packaging (SET)

Trials testing the same drug.

NCT03079089 — Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refr · NA · completed

Other recruiting trials for Refractory Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT06871410 — Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT07263906 — Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia · Phase 1 · recruiting
NCT07025564 — MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06928662 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant · Phase 1, PHASE2 · recruiting
NCT06484062 — Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M · Phase 1 · recruiting

Other Association for Training, Education, and Research in Hematology, Immunology, and Transplantation trials

Trials by the same sponsor.

NCT03079089 — Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refr · NA · completed
NCT02439476 — Non-interventional Study on Salvage Auto in Relapsed Myeloma · completed
NCT02504190 — Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03035422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03035422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing